CARB‑X awarded two diagnostic developers new funding to advance point‑of‑care tests addressing pediatric respiratory infections and sexually transmitted infections. ProtonDx received $1 million to evaluate a blood‑based host RNA signature assay for lower respiratory tract infections in children, integrating Imperial College London biomarkers with ProtonDx’s Lacewing instrument. The work targets less invasive sampling and faster clinical decisions to curb antibiotic misuse. Scout Health was granted up to $6 million to finalize a next‑generation low‑cost loop‑mediated isothermal amplification (LAMP) test for chlamydia and gonorrhea, with pilot studies planned in low‑ and middle‑income countries. Both awards reflect CARB‑X’s focus on affordable, rapid diagnostics that can reduce empirical antibiotic prescribing and surveillance gaps in LMICs.